Previous 10 | Next 10 |
invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies. Xuanzhu Biopharm of Shandong out-licensed China rights for two anti-infectives to Shanghai SPH New Asia Pharma in ...
Gainers: Fujian Blue Hat Interactive Entertainment Technology (BHAT) +323%. F-star Therapeutics (FSTX) +59%. Rain Therapeutics (RAIN) +43%. The9 Limited (NCTY) +36%. Vroom (VRM) +33%. MSP Recovery (MSPR) +23%. uniQure (QURE) +22%. Azure Power Global (AZRE) +22%. Valneva (VALN) +21%. Anebulo P...
Gainers: F-star Therapeutics (FSTX) +57%. Valneva (VALN) +23%. Nutriband (NTRB) +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics (APLT) -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) ...
Proposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwide The transaction demonstrates the strength of F-st...
Gainers: 22nd Century Group (XXII) +29%. Wave Life Sciences WVE +16%. Codex DNA (DNAY) +13%. F-star Therapeutics (FSTX) +12%. Sorrento Therapeutics (SRNE) +12%. Losers: Athira Pharma ATHA -70%. Neptune Wellness Solutions NEPT -32%. 4D pharma (LBPS)...
F-star Therapeutics press release (NASDAQ:FSTX): Q1 GAAP EPS of -$0.57 beats by $0.11. Revenue of $2.55M (-12.7% Y/Y) beats by $0.99M. For further details see: F-star Therapeutics GAAP EPS of -$0.57 beats by $0.11, revenue of $2.55M beats by $0.99M
Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting Company To Host Conference Call Today at 9...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced t...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced...
F-star Therapeutics Inc. (NASDAQ:FSTX) traded at a new 52-week high today of $15.99. So far today approximately 5.8 million shares have been exchanged, as compared to an average 30-day volume of 133,000 shares. F-star Therapeutics Inc. share prices have moved between a 52-week high of $1...
News, Short Squeeze, Breakout and More Instantly...
F-star Therapeutics Inc Com Company Name:
FSTX Stock Symbol:
NASDAQ Market:
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWI...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...